Clinical Trial Detail

NCT ID NCT04301778
Title Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

intrahepatic cholangiocarcinoma

Therapies

Durvalumab + SNDX-6352

Age Groups: senior adult

No variant requirements are available.